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Background: Abdominal aortic aneurysm (AAA) is a dilatation of the aorta affecting most frequently elderly men.
Histologically AAAs are characterized by inflammation, vascular smooth muscle cell apoptosis, and extracellular
matrix degradation. The mechanisms of AAA formation, progression, and rupture are currently poorly understood. A
previous mRNA expression study revealed a large number of differentially expressed genes between AAA and
non-aneurysmal control aortas. MicroRNAs (miRNAs), small non-coding RNAs that are post-transcriptional regulators
of gene expression, could provide a mechanism for the differential expression of genes in AAA.
Methods: To determine differences in miRNA levels between AAA (n = 5) and control (n = 5) infrarenal aortic
tissues, a microarray study was carried out. Results were adjusted using Benjamini-Hochberg correction (adjusted
p < 0.05). Real-time quantitative RT-PCR (qRT-PCR) assays with an independent set of 36 AAA and seven control
tissues were used for validation. Potential gene targets were retrieved from miRNA target prediction databases
Pictar, TargetScan, and MiRTarget2. Networks from the target gene set were generated and examined using the
network analysis programs, CytoScape® and Ingenuity Pathway Core Analysis®.
Results: A microarray study identified eight miRNAs with significantly different expression levels between AAA and
controls (adjusted p < 0.05). Real-time qRT-PCR assays validated the findings for five of the eight miRNAs. A total of
222 predicted miRNA target genes known to be differentially expressed in AAA based on a prior mRNA microarray
study were identified. Bioinformatic analyses revealed that several target genes are involved in apoptosis and
activation of T cells.
Conclusions: Our genome-wide approach revealed several differentially expressed miRNAs in human AAA tissue
suggesting that miRNAs play a role in AAA pathogenesis.
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Abdominal aortic aneurysm (AAA) is a dilatation of the
aorta (>3 cm) that occurs below the renal arteries [1]. In
the majority of cases AAA is asymptomatic until it
reaches a size that requires surgical intervention due to
increased risk of rupture, which is often fatal. The only
option for patients diagnosed with AAA ≥55 mm is sur-
gical repair of the aorta, but the risk of surgery must be
weighed with the risk of rupture. For patients with smal-
ler AAAs, there is currently no treatment. The most* Correspondence: shkuivaniemi@geisinger.edu
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reproduction in any medium, provided the orimportant known risk factors for AAA include smoking,
male sex, family history, and advanced age [1,2]. Add-
itionally, biomechanical analyses of AAA demonstrated
that there are many factors contributing to aortic wall
strength [3]. Previous studies have shown that AAA has
a strong genetic component [4], but the biological
mechanisms of AAA are not fully understood [2,5].
AAA is characterized by the apoptosis of smooth muscle
cells, degradation of the extracellular matrix, a potent
inflammatory response, and increased oxidative stress in
the abdominal aortic wall [2,5-8]. Infiltration by inflam-
matory cells may act as mediators that lead to apoptosis
of vascular smooth muscle cells [7]. A previous genome-
wide mRNA expression study identified a large number. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AAA compared to abdominal aortic tissues from age-
and sex-matched controls [9].
MicroRNAs (miRNAs) are a class of small non-coding
RNAs, whose primary function is the post-transcriptional
regulation of gene expression. miRNAs are incorporated
into the RNA induced silencing complex (RISC) and
preferentially bind to the 3’ untranslated region (3’UTR)
of target mRNA. RISC then inhibits gene expression by
either mRNA degradation or by inhibiting translation
[10]. miRNAs have been predicted to regulate thousands
of target genes [11], which belong to many biological
pathways including immune response and apoptosis [12].
Recent studies have demonstrated that miRNAs play roles
in several cardiovascular diseases [13].
In the current study, we investigated the expression
patterns of microRNAs in AAA as a potential mechanism
for the differences in gene expression observed in our prior
study [9]. A microarray-based genome-wide screening
study was followed by assaying miRNAs individually with
real-time quantitative RT-PCR (qRT-PCR). Bioinformatic
analyses were carried out to predict gene targets of the
miRNAs and analyze their potential roles in AAA.
Methods
Human aortic samples
Full thickness aortic wall tissue specimens were collected
from patients undergoing AAA repair operations (n = 41)
at the Geisinger Medical Center, Danville, Pennsylvania,
USA, or at the Department of Visceral, Thoracic and
Vascular Surgery, Technical University of Dresden, Dresden,
Germany. Non-aneurysmal aortic samples (n = 12) were
collected at autopsies or were obtained from the National
Disease Research Interchange (NDRI, Philadelphia, PA;
www.ndriresource.org). Tissue samples for RNA isolation
were stored in RNAlater (Ambion, Austin, TX) or snap-
frozen. Table 1 summarizes the demographics of the
different groups used in the microarray and qRT-PCR
studies. All samples used in the study and information
about the donors are listed in Additional file 1: Table S1.
The investigation conformed to the principals outlined in
the Declaration of Helsinki. AAA patients gave writtenTable 1 Summary of experimental groups
Group N Age (Years ± SD) Sex
Control – MA 5 65.4 ± 9.8 3 M, 2 F
eAAA – MA 5 64 ± 3.9 3 M, 2 F
Control - PCR 7 64.6 ± 4.2 7 M
eAAA – PCR 25 70.5 ± 6.1 23 M, 2 F
rAAA – PCR 11 71.9 ± 9.1 10 M, 1 F
MA, microarray; PCR, qRT-PCR; M, male; F, female; eAAA, elective repair for
AAA; rAAA, ruptured AAA.
For detailed information on donors, see Additional file 1: Table S1.informed consent for the use of their aortic tissue samples
for research. The collection of the human tissues was
approved by the Institutional Review Board of Geisinger
Clinic, Danville, Pennsylvania, USA, and the Ethics
Committee of the Medical Faculty at the Technical
University of Dresden, Germany.
RNA isolation
RNA was isolated with mirVana™ miRNA Isolation Kit
(Ambion Applied Biosystems, Austin, TX). Quality of
the RNA samples was assessed by 2100 Bioanalyzer
(Agilent Technologies, Inc., Santa Clara, CA).
Microarray study
miRNA expression was compared in AAA (n = 5) and
control (n = 5) samples using an Affymetrix GeneChip
miRNA 1.0 Array (Santa Clara, CA). The microarray
contained 847 miRNAs probes and 922 probes for other
small non-coding RNAs. The expression values were
computed using the R package Affycoretools version
1.24.0 (available at http://bioconductor.org/) Robust
Multivariate Average [14]. miRNAs were identified by
calculating the Empirical Bayes Statistics using the R
package Limma [15]. Benjamini-Hochberg correction was
applied to control the false discovery rate (FDR) [16].
Previously our laboratory generated global mRNA
expression profiles for both aneurysmal and non-
aneurysmal human infrarenal abdominal aorta [9]. The
microarray data can be obtained at the Gene Expression
Omnibus (GEO) database (Series# GSE7084; http://www.
ncbi.nlm.nih.gov/geo/). We used this data set here for the
target gene analysis (see below).
Real-time quantitative reverse transcriptase-polymerase
chain reaction
Eight miRNAs (miR-133a, miR-133b, miR-146 a, miR-
181a*, miR-204, miR-21, miR-30c-2*, miR-331-3p) which
showed significant differences in their levels with an
adjusted p < 0.05 in the microarray experiment were
selected for qRT-PCR validation. TaqMan® MicroRNA
Assays for these miRNAs and a small non-coding RNA
U6 (Applied Biosystems, Carlsbad, CA) were run
according to manufacturer’s recommendation first on
RNA from twelve AAA samples from patients undergo-
ing elective repair of an aneurysm and seven control
samples that were independent of the microarray study
(Table 1 and Additional file 1: Table S1). Next, for the
subset of miRNAs with expression medians and variance
that warranted further investigation, we expanded the
study with an additional thirteen AAA samples from
patients undergoing elective repair and eleven AAA
samples from patients with aneurysm rupture for a total
of seven control, 25 elective repair AAA, and eleven
ruptured AAA samples. The relative expression levels of
Figure 1 Volcano plot demonstrating differences in expression
levels of miRNAs between AAA and control abdominal aorta
based on the microarray study. The log-fold change is plotted
against the log odds of differential expression using the R package
limma. The miRNAs with significant differences in expression levels
between the AAA (n = 5) and control (n = 5) groups (p < 0.05) after
Benjamini-Hochberg correction are indicated. Complete lists of
nominally significant miRNAs and snoRNAs are shown in Additional
file 2: Table S2 and Additional file 3: Table S3, respectively.
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the expression of the small non-coding RNA U6 as an
internal control. The p values were calculated using the
Wilcoxon rank-sum test using the statistical program R
version 2.13.1 (R Foundation for Statistical Computing,
Vienna, Austria).
Bioinformatic Analyses
Targets were predicted for qRT-PCR validated miRNAs
(miR-133a, miR-133b, miR-331-3p, and miR-204), which
were all down regulated in AAA. miR-30c-2* was not
included because it is a miRNA* strand; passenger (*)
strands of miRNA are usually degraded upon uploading
of the miRNA duplex into the RISC complex [17]. The
miRNA target prediction databases TargetScan, MirTarget2,
and Pictar were queried using the R package RmiR.hsa [18].
The predicted targets were then compared to a list of upre-
gulated genes found in our previous study [9]. In addition,
we queried targets of miR-331-3p from TargetScan's non-
conserved target prediction dataset (http://www.targetscan.
org/) and retrieved gene targets that were conserved across
placental mammals.
To evaluate the strength of the binding of miRNAs to
their targets, the minimum free energy for miRNA–
mRNA hybridization was calculated using program
RNAhybrid version 2.1. [19]. The median minimum free
energy of hybridization was taken for genes with
multiple transcripts. For this analysis the miRNA
sequences of qRT-PCR validated miRNAs were retrieved
from miRbase version 17 (http://www.mirbase.org). The
sequences of the target gene 3’UTR were retrieved from
Ensemble Biomart (http://useast.ensembl.org/). CytoScape®,
version 2.8.1 software available at http://www.cytoscape.org
[20] was used to generate a network showing the miRNA-
mRNA connections and indicating the strength of the
binding based on the minimum free energy values.
Functional classification of the target genes was carried
out with Gene Ontology (GO) analysis using WebGestalt
to create a hierarchy of the GO annotations of the pre-
dicted targets (http://bioinfo.vanderbilt.edu/webgestalt/).
For this procedure, a list of the Entrez IDs for predicted
targets that were known to be differentially expressed
based on our previous study [9] was uploaded to the web
application WebGestalt Gene Set Analysis Toolkit Version
2 [21]. Directed acyclic graphs (DAGs) were generated
representing a hierarchical categorization of the significant
GO annotations.
Potential target gene interactions were analyzed via net-
works generated using Ingenuity Pathway Analysis® (IPA)
tool version 9.0, (Ingenuity Systems, www.ingenuity.com).
The four biologically active qRT-PCR-validated miRNAs
with their targets were uploaded to IPA. Since IPA
combines the targets of mature miRNAs with similar
sequences (2–3 nucleotide difference) to miRNA families,experimentally validated targets of miR-133a/miR-133b,
miR-211/204, and miR-331-3p were retrieved.
Results and Discussions
A microarray study was performed comparing miRNA
expression levels in infrarenal aortic tissue samples
between AAA (n = 5) and age- and sex-matched controls
(n = 5) (Table 1). The empirical Bayes statistics revealed
that out of the 847 miRNAs probes and 922 probes for
other small non-coding RNAs, eight miRNAs and one
snoRNA had significantly different expression (adjusted
p < 0.05 after applying Benjamini Hochberg correction;
Figure 1) [16]. The three upregulated miRNAs were
miR-181a* (MIMAT0000270), miR-146a (MIMAT0000449),
and miR-21 (MIMA0000076), while five miRNAs, miR-
133b (MIMAT0000770), miR-133a (MIMA000427), miR-
331-3p (MIMAT0000760), miR-30c-2* (MIMAT0004550),
and miR-204 (MIMA0000265), were significantly down
regulated (Figure 1). In addition, HBII-85-29, a small nucle-
olar RNA, C/D box 116–29, was found to be significantly
down regulated (Figure 1). The full lists of the 139 miRNAs
and 78 other small non-coding RNAs with expression
differences with nominal p < 0.05 (no correction for
multiple testing) are shown in Additional file 2: Table S2,
and Additional file 3: Table S3, respectively.
The expression levels of the eight miRNAs identified
in the microarray study were initially validated using
individual real-time qRT-PCR assays and a new set of
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(Table 1 and Additional file 1: Table S1). The five down
regulated miRNAs showed significantly different expres-
sion in AAA tissue compared to the control infrarenal
abdominal aorta samples, but the three up regulated
miRNAs failed to replicate (Figure 2A). Since it is plaus-
ible to hypothesize that AAA initiation, growth and rup-
ture have different molecular mechanisms, we compared
the expression levels of the five qRT-PCR-validated miR-
NAs in ruptured (n = 11) and non-ruptured, electively
repaired (n = 25) AAAs (Figure 2B). No significant differ-
ences were found between the AAA samples from
patients undergoing elective repair operations (eAAA)
and those with ruptured AAA (rAAA; Figure 2B). In the
combined qRT-PCR analysis including all the 36 AAA
tissue samples and seven controls, the differences in
expression levels of the five miRNAs, miR-133b, miR-133a,
miR-331-3p, miR-30c-2*, and miR-204, between AAA and
control groups were highly significant (Figure 2).
We searched the literature for information on miR-
133b, miR-133a, miR-204, miR-331-3p, and miR-30c-2*,
the five miRNAs with confirmed downregulated expres-
sion between AAA and control abdominal aorta. The
functions of miR-133b, miR-133a, and miR-204 have
been thoroughly examined in a cardiovascular context
[22-28], but nothing was known about their role in





























































** *** *** * ** NS NSNS
A
Figure 2 Validation of microarray results by real-time qRT-PCR in an i
significantly different between AAA and controls in the microarray study w
seven control samples. B. Five down regulated miRNAs validated by qRT-PC
from elective AAA repairs (eAAA) and eleven samples from ruptured AAAs
expression levels of U6. The p values were calculated using the Wilcoxon ra
significant; *, p < 0.05; **, p < 0.001; ***, p < 0.0001.found several miRNAs with nominally significant (p < 0.05)
differences when compared to normal thoracic aorta (sum-
marized in Additional file 2: Table S2). Of the validated
miRNAs in the current study only miR-133a and miR-133b
differed in expression also in thoracic aortic dissections
compared to controls [29]. The differences in the results of
these two studies reinforce the distinct nature of these two
aortic diseases.
While the current study was under review miR-21 and
miR-29b (MIMAT0000100) were identified as potential
therapeutic targets in an animal model of aortic aneur-
ysms [30,31]. In addition, miR-21 was shown to be upre-
gulated in human AAA tissue using qRT-PCR [30].
Although miR-21 was upregulated in AAA in our micro-
array study (Figure 1), it was not validated by qRT-PCR
(Figure 2A). The discordant results could be due to
differences in ages of the control subjects in the two
studies. We did not detect significant differential expression
of miR-29b; however, miR-29b-2* was downregulated in
our microarray study before FDR correction (Additional file
2: Table S2).
We characterized the putative functions of the miR-
NAs by identifying genes they are predicted to regulate.
Predicted targets for miR-133a, miR-133b, miR-331-3p,
and miR-204 were retrieved from the miRNA–mRNA
target databases TargetScan, Pictar, and MirTarget2 with
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(rAAA). The expression levels for each miRNA were adjusted to the
nk-sum test. Significance between each comparison is shown. NS, not
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MirTarget2 data sets [11,32,33]. The list of predicted
targets was compared to a list of genes that were previously
identified as having altered expression levels in AAA from
our microarray-based mRNA expression study [9]. The
four downregulated miRNAs miR-133a, miR-133b, miR-
331-3p, and miR-204 had 1,836 potential target genes, 222
of which were significantly upregulated in our prior mRNA
microarray study (Additional file 4: Table S4) [9], consistent
with the proposed regulatory action of the miRNAs.
We explored further the miRNA–mRNA interactions
with the downloadable version of RNAhybrid program
to compute the minimum free energy of the miRNA–
mRNA binding [19]. The rationale for this analysis is
that interactions with lower predicted minimum free en-
ergy are predicted to be more stable and more likely to
occur. We ranked the miRNA–target gene interactions
and generated a network using CytoScape® to visualize
the predicted miRNA–mRNA interactions (Figure 3).
There was a redundancy between the predicted targets
of miR-133a and miR-133b due to the similarity in their
sequences; however, the two base pair difference had an
impact on the calculated minimum free energies,
suggesting that they may have different affinities for
individual target silencing [19]. In general miR-331-3p
had the lowest calculated minimum free energy of
hybridization to its predicted targets, which suggests it
may have stronger binding affinity for its targets.
Several genes were identified as potential targets of
two or more of the miRNAs (Figure 3). Four genes
(CSRNP1, SLC7AB, PLK3, and FURIN) were predicted
targets of miR-133a/miR-133b and miR-331-3p. Two
genes (APH1A and VHL) were predicted targets of miR-
204 and miR-331-3p. Eight genes (DNM2, DNAJB1,
TGFBR1, TGOLN2, BCL11A, EDEM1, SFXN2, YTHDF3)
were predicted targets of miR-204 and miR-133a/miR-
133b. Hypermethylated in cancer 2 (HIC2) was the only
gene predicted to be targeted by all four miRNAs (Figure 3).
Although the function of HIC2 has not been extensively
studied, it is closely related to HIC1, which is an important
tumor suppressor gene that deactivates repressors of P53
and E2F1 induced senescence [34].
We analyzed the GO terms to assign potential func-
tions to the miRNA targets using the web application,
WebGestalt [21]. The results with the most enriched
biological processes and molecular functions are shown
as a DAG in Figure 4. The most significant biological
function was the “positive regulation of apoptosis”
(Figure 4). It was interesting given the fact that smooth
muscle cell apoptosis is a characteristic histological feature
of aneurysmal aortic wall in humans. Previous cell culture
studies, however, have shown a role for miRNAs in smooth
muscle cell proliferation [27,35]. A possible explanation for
the contradictory results could be that we are looking atlate stages of the human aneurysmal disease requiring
surgical intervention, while the previously published cell
culture experiments on smooth muscle cells [25] may be
more relevant to the initial stages of arterial wall injury.
This conclusion is supported by other studies in which
mice treated with antagomirs for miR-133a showed cardio-
myocyte hypertrophy [25], but knockout mice lacking
miR-133a displayed dilated cardiomyopathy with increased
apoptosis [22,25]. Another possible explanation is that
our results indicate high turnover of vascular smooth
muscle cells.
Several target genes with functions in apoptosis were
of interest in AAA. Two tumor necrosis factor receptors,
TNFRSF10B and TNFRSF8, were predicted targets of miR-
133a/miR-133b and miR-204, respectively. TNFRSF10B,
also known as death receptor 5, is involved in DR5/FADD/
caspase-8 signaling and is an important component of the
extrinsic apoptotic pathway [36]. TNFRSF8, also known as
CD30, is involved in NFκB activation and is expressed by
activated T and B cells [37]. Tumor protein p53-inducible
nuclear protein 1 (TP53INP1) is a p53 target gene that
responds to multiple types of cellular stress events,
including oxidative stress, and promotes cell cycle arrest
and apoptosis [38].
Another significant GO term among the target genes
included “T cell activation” (Figure 4), which is highly
relevant finding to AAA, since inflammation is a character-
istic of AAA [5], and antigen-independent co-stimulation
is a crucial step in T cell activation [39]. CD28, CD86, and
ICOS, which are important co-stimulatory molecules, were
predicted to be targets of miR-204, miR-133a/miR-133b,
and miR-331-3p, respectively [40]. CD28 and ICOS are
important receptors of co-stimulatory signals, which are
triggered by ICOSL in human vascular endothelial cells
[39]. CD86, which is expressed in antigen presenting cell
types including dendritic cells, macrophages, and B cells
[41], acts as a ligand to CD28. CD86 is not expressed in
endothelial cells [40], but its levels are elevated in the
plasma [42] of AAA patients. Furthermore, the mRNA
levels of CD86, CD80, CTLA, and ICOS are elevated in the
aortic wall of AAA patients [9].
“Response to organic substance” and “purinergic
nucleotide receptor activity” were additional significant
GO terms among the upregulated target genes (Figure 4).
Approximately half of the genes annotated in “Response to
organic substance” were also genes annotated as apoptotic
genes. Four of the genes (DUSP4, AQP9, SOCS1, and
PTPN2) are involved in injury response [43-46]. Genes
which were annotated to play roles in responding to
organic substance included the niacin receptors, GPR109A
and GPR109B. Niacin has been studied for its potential use
based on its anti-inflammatory and anti-atherosclerotic
effects of raising HDL [47], although no benefit to patients
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Figure 3 A network of miRNAs miR-133a, miR-133b, miR-331-3p, miR-204, and their target genes. miR-30c-2* was not included because it
is a miRNA* strand that is usually degraded upon miRNA loading to the RISC complex [17]. Bioinformatic analysis predicted 222 genes
(see Additional file 4: Table S4) with upregulated expression in AAA based on a prior microarray study [9] were targets of miR-133a, miR-133b,
miR-331, or miR-204. The predicted minimum free energy of the miRNA and target mRNA hybridization from RNAhybrid is shown by the line and
node color. Black lines indicate that the 3'UTR sequence was not available from Biomart, and the minimum free energy was not calculated. The
figure was generated using CytoScape® [20].
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generate a network from 45 experimentally verified
interactions of the four biologically active, validated,
down regulated miRNAs (miR-133a, miR-133b, miR-
331-3p, and miR-204) (Figure 5). We further explored
the regulation of the targets by examining the interac-
tions of the validated targets with the predicted miRNA
targets (Figure 6), and found that 54 of the predicted
miRNA targets interacted with the experimentally
validated miRNA targets. The interaction networks
(Figures 3, 5, and 6) demonstrate a complex role for
miRNAs in AAA. Since miRNAs usually inhibit mRNA
expression of their target genes [10], we expected that
target mRNAs of the miRNAs down regulated in AAA
would be upregulated; several gene targets exhibited
expression levels consistent with this expectation (shownin red in Figure 5). For example, MMP9 was identified
as a target of miR-204 [49]. This finding is highly
relevant to AAA pathogenesis, since the decreased level
of miR-204 could contribute to the increased mRNA
and protein expression level of MMP9 seen in human
AAA tissue (Figures 5 and 6), and thereby increase the
degradation of the extracellular matrix in AAA [50].
There were also several genes known to be regulated
by these miRNAs whose expression was decreased in
AAA (shown in green in Figure 5) [9]. Most of these
genes have proliferative and anti-apoptotic functions
based on our literature search. For example, in cell cul-
ture experiments, miR-133a/miR-133b down regulation is
associated with a switch in vascular smooth muscle cells
to a proliferative phenotype [27]. miR-133a regulates the
































































































































































































Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Biological categories of miRNA target genes. A DAG of the GO categories of the set of 222 upregulated mRNAs was generated by
the web application WebGestalt. Categories shown in red were significant (adjusted p < 0.001).
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a ubiquitously expressed member of the NFAT transcrip-
tion factor family and is involved in cell proliferation.
NFATC4 mediates the effect of miR-133a in increasing
cell proliferation in cardiomyocyte hypertrophy in vivo
[24], but its expression is decreased in AAA [9]. One
potential explanation for the down regulation of NFATC4
is competition with other biological pathways. HOXA9
indirectly promotes NFATC4 expression [51,52]. TheFigure 5 A network of the interactions of the miRNA target genes. In
experimentally observed miRNA–mRNA interactions of miR-133a/miR-133b
expression) and green (decreased expression) were identified in our previo
dashed lines indirect interactions.expression of the members of the HOXA family is
decreased in AAA [53]. Also, in hypertrophy NFATC4 is
regulated by calcium mediated response of angiotensin II,
endothelin, and norepinephrine binding to their receptors
[54], but in AAA the expression of these receptors is
down regulated [9]. KLF15 is also a target of miR-133a/
miR-133b [23], and its expression is reduced in both
mouse aneurysm models and human AAA [9,55]. These
findings suggest that multiple competing regulators aregenuity Pathway Analysis® tool was used to generate the network from
, miR-204, and miR-331-3p. Molecules shown in red (increased
us microarray study [9]. Solid lines represent direct interactions and
Figure 6 Expanded network of the validated miRNA–mRNA interactions. The network was generated using Ingenuity Pathway Analysis®
tool. The validated network shown in Figure 5 was expanded to include experimentally validated interactions with our list of the 222 predicted
miRNA targets (Additional file 4: Table S4). Green molecules are the four down regulated miRNAs (miR-133a/miR-133b, miR-204, and miR-331-3p),
yellow molecules are experimentally verified target genes of the four miRNAs, and grey molecules are predicted targets of the four miRNAs. Solid
lines represent direct connections and dashed lines represent indirect connections.
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complex interactions between regulatory molecules with
different functions.
Our study has several limitations. One limitation is the
use of end-stage disease human tissue, since it is plaus-
ible to collect human aortic aneurysmal samples only
from AAAs large enough to require surgical intervention
or from ruptured aortas. Additionally, since the study is
observational, it is not possible to differentiate between
cause and consequence, which would require interven-
tion in a model system. It is also possible that the differ-
ences in mRNA and miRNA expression are merely
reflective of the changes in the aortic wall architecture
in AAA. The histological characterization of the aortic
wall in AAA to “inflammatory”, “active” and “amorphous
regions” has been proposed [56,57]; the regions may,
however, overlap and do not necessarily show a clear
progression of the disease. Based on histological and
immunohistochemical analyses in our previous studies
[58,59], the samples were from the so called “active
region” of the AAAs.
Conclusions
Our genome-wide study followed by qRT-PCR validation
identified five miRNAs with significantly downregulated
expression in AAA aortic tissue from a control group of
human infrarenal aortic tissues. Bioinformatic analysis
indicated that miR-133a, miR-133b, miR-331-3p, and
miR-204 target apoptotic genes, which may play a role
in the loss of vascular smooth muscle cells in AAA. The
miRNAs are also involved in the activation of the
immune cells and the alteration of their response to
chemical signaling. Taken together, the results provide
strong evidence for an important regulatory function of
miRNAs in vascular remodeling of the aorta.
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